Literature DB >> 16751933

Prophylaxis of deep-vein thrombosis after lower extremity amputation: comparison of low molecular weight heparin with unfractionated heparin.

Sidney Lastória1, Hamilton A Rollo, Winston Bonetti Yoshida, Mariangela Giannini, Regina Moura, Francisco H A Maffei.   

Abstract

PURPOSE: To compare the efficacy and safety of a low molecular weight heparin (enoxaparin) with unfractionated heparin (UH) in this prophylaxis.
METHODS: Seventy five patients (59 men and 16 women), undergoing major lower extremity amputation (30 above-knee and 45 below-knee), were randomized to be treated with subcutaneous UH (5,000 IU t.i.d.) or enoxaparin (40 mg/day) during hospitalization. Prophylaxis was started 12 hours before surgery or, in emergency cases, in the first postoperative day.
RESULTS: The two groups were comparable with regard to baseline characteristics. Evaluation of DVT was performed by daily clinical examination and by duplex scanning before and 5 to 8 days after surgery. DVT was documented in the operated limb in 9.75% in patients treated with enoxaparin and in 11.76% in patients treated with UH (p=0.92) and there was one bilateral thrombosis in each group . Bleeding complications were not observed in both groups.
CONCLUSION: Enoxaparin and UH were both efficient and safe for the prophylaxis of DVT in patients submitted to lower extremity amputation.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16751933     DOI: 10.1590/s0102-86502006000300011

Source DB:  PubMed          Journal:  Acta Cir Bras        ISSN: 0102-8650            Impact factor:   1.388


  7 in total

1.  Prevention of VTE in nonorthopedic surgical patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

Authors:  Michael K Gould; David A Garcia; Sherry M Wren; Paul J Karanicolas; Juan I Arcelus; John A Heit; Charles M Samama
Journal:  Chest       Date:  2012-02       Impact factor: 9.410

Review 2.  Unfractionated heparin versus low molecular weight heparins for avoiding heparin-induced thrombocytopenia in postoperative patients.

Authors:  Daniela R Junqueira; Liliane M Zorzela; Edson Perini
Journal:  Cochrane Database Syst Rev       Date:  2017-04-21

3.  F11 rs2289252T and rs2036914C Polymorphisms Increase the Activity of Factor XI in Post-trauma Patients with Fractures Despite Thromboprophylaxis.

Authors:  Nan Song; Ai-Xian Tian; Jian-Min Zhang; Hong-Qiang Jiang; Jia-Cheng Zang; Xin-Long Ma
Journal:  Orthop Surg       Date:  2016-08       Impact factor: 2.071

4.  Rat and human HARE/stabilin-2 are clearance receptors for high- and low-molecular-weight heparins.

Authors:  Edward N Harris; Bruce A Baggenstoss; Paul H Weigel
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2009-04-09       Impact factor: 4.052

5.  Impact of screening versus symptomatic measurement of deep vein thrombosis in a national quality improvement registry.

Authors:  Randall R De Martino; Adam W Beck; Matthew S Edwards; Matthew A Corriere; Jessica B Wallaert; David H Stone; Jack L Cronenwett; Philip P Goodney
Journal:  J Vasc Surg       Date:  2012-07-24       Impact factor: 4.268

6.  Primary prophylaxis for venous thromboembolism in people undergoing major amputation of the lower extremity.

Authors:  David Rb Herlihy; Matthew Thomas; Quoc H Tran; Vikram Puttaswamy
Journal:  Cochrane Database Syst Rev       Date:  2020-07-21

7.  All-Cause Mortality Amongst Patients Undergoing Above and Below Knee Amputation in a Regional Vascular Centre within 2014-2015.

Authors:  Gem Kennedy; K McGarry; G Bradley; D W Harkin
Journal:  Ulster Med J       Date:  2019-01-22
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.